Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant

Experimental and Clinical Transplantation

Volumn 11, Issue 6, 2013, Pages 494-498

  Soliman, Amin R ^a   Fathy, Ahmed ^a   Khashab, Sahier ^a   Shaheen, Noha ^a   Soliman, Mahmoud A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Dpp 4; Glargine; Hyperglycemia; Insulin; Kidney; Weight

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN GLARGINE; METFORMIN; SITAGLIPTIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY GRAFT; MALE; MIDDLE AGED; MONOTHERAPY; NAUSEA; NEW ONSET DIABETES MELLITUS AFTER TRANSPLANT; RANDOMIZED CONTROLLED TRIAL; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; KIDNEY TRANSPLANTATION; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES; WEIGHT GAIN; WEIGHT LOSS;

EID: 84890495064     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2013.0018     Document Type: Article

References (20)

1. Oterdoom LH, de Vries AP, van Son WJ, et al. Validation of insulin resistance indexes in a stable renal transplant population. Diabetes Care. 2005;28(10):2424-2429
2. Sharif A, Ravindran V, Moore RH, et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. Transplantation. 2010;89(3):327-333. doi: 10.1097/TP.0b013e3181bbf2c4
3. Luan FL, Stuckey LJ, Ojo AO. Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation. Transplantation. 2010;89(8):1034-1039. doi: 10.1097/TP.0b013e3181d05a90
4. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48(1):141-151
5. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675-688
6. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612-4619
7. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47(11):1663-1670
8. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs. 2004;13(9):1091-1102
9. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 2004;4(6):589-596
10. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-E206
11. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644-649
12. Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138(12):952-959
13. Pinelli NR, Nemerovski CW, Koelling TM. Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. Transplant Proc. 2011;43(5):2113-2115. doi: 10.1016/j.transproceed.2011.02.059
14. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011;92(10):e56-e57. doi: 10.1097/TP.0b013e3182347ea4
15. Shah A, Kendall G, Demme RA, et al. Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. Transplantation. 2005;80(6):775-781
16. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol. 2010;21(3):383-385. doi: 10.1681/ASN.2010010031
17. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7(6):1506-1514. Epub 2007 Mar 12. Erratum in: Am J Transplant. 2008;8(1):1. Am J Transplant. 2008;8(4):908. Dosage error in article text.
18. Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors. Transplantation. 1991;51(2):343-347
19. Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009;4(4):853-859. doi: 10.2215/CJN.05471008
20. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739-749. doi: 10.1681/ASN.2011080835.